New strategy aims to extend First-Line cancer treatment success
NCT ID NCT07545486
First seen Apr 29, 2026 · Last updated May 05, 2026 · Updated 2 times
Summary
This study tests whether destroying remaining cancer spots (local ablative therapy) after initial treatment can keep the disease under control for longer. It includes 1235 adults with various solid tumors whose cancer did not worsen after three months of standard first-line therapy. The goal is to see if this approach extends the time before the cancer grows again, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American University of Beirut (AUB)
Beirut, Lebanon
Contact
Contact
-
Bank of Cyprus Oncology
Nicosia, 2006, Cyprus
Contact
Contact
-
CHIREC Hospital
Brussels, 1160, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU Brugmann
Brussels, 1020, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Saint-Etienne
Saint-Priest-en-Jarez, 42270, France
Contact
Contact
-
Centre de Lutte contre le Cancer François Baclesse
Caen, 14000, France
Contact
Contact
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Grand Hôpital de Charleroi, site Notre Dame
Charleroi, 6000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HELORA Hôpital de Mons - Site Kennedy
Mons, 7000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Universitaire de Strasbourg
Strasbourg, 67200, France
Contact
Contact
-
Institut Paoli-Calmettes
Marseille, 13009, France
Contact
Contact
-
Oslo University Hospital / The Norwegian Radium Hospital
Oslo, Norway
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.